A clinical trial found that women could switch drugs without waiting for scans showing cancer progression, which improved ...

The Phase III trial showed that the new targeted therapy, inavolisib (Itovebi), provides significant survival benefits for ...

The lead author said the study also showed the inavolisib-based therapy "more than doubled the time before their cancer progressed or worsened".

First-line treatment with the triplet combination of encorafenib, cetuximab and mFOLFOX6 significantly improved survival ...

Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was ...

Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was ...